Athena Athena

X
[{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","amount":"$26.5 million","upfrontCash":"Undisclosed","newsHeadline":"Scioto Biosciences Receives Series B Investment from Genome & Company","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scioto Biosciences, Inc. Announces Top-Line Results of SB-121 in a Phase Ib Trial in Patients Diagnosed With Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scioto Biosciences Announces Publication of Phase 1b Study in Autism","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Scioto Biosciences

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            SB-121 is a novel formulation of Lactobacillus reuteri (Lr) and was given to patients 15 to 45 years of age diagnosed with ASD. With the results now published, the study demonstrated that SB-121 was safe and well-tolerated.

            Lead Product(s): SB-121

            Therapeutic Area: Neurology Product Name: SB-121

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Top-line results from the study demonstrated that SB-121 (Lactobacillus Reuteri), represents the first clinical validation of ABT platform was safe and well tolerated.

            Lead Product(s): Lactobacillus Reuteri,Sephadex,Maltose

            Therapeutic Area: Neurology Product Name: SB-121

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 26, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Funding will be used to support ongoing clinical development of Scioto’s lead product, SB-121, as a microbiome treatment for diseases affecting the gut-brain axis and gut injury.

            Lead Product(s): SB-121

            Therapeutic Area: Gastroenterology Product Name: SB-121

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Genome & Company

            Deal Size: $26.5 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing August 11, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY